A Retrospective, Non-interventional Study to Evaluate EGFR-Tyrosine Kinase Inhibitor Retreatment in Patients with Locally Advanced or Metastatic EGFR Mutated NSCLC who Previously Treated with EGFR-TKI as First-line Therapy and Chemotherapy as Second-line Therapy – SEQUENCE study
Locally Advanced or Metastatic EGFR Mutated NSCLC.
20 Years - 150 Years
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Oct 2014 by AstraZeneca
No locations available